Halozyme Therapeutics (HALO) Advances +30.1% in 30 Days on Q2 Results and Raised Guidance
Key Takeaways
- HALO shares advanced approximately 30.1% during the 30 days ended August 14, 2026, based on an available price of $98.63 versus a closing price of $75.82 on July 15.
- The move was driven primarily by second-quarter 2026 results released August 6, including revenue of $481 million and non-GAAP diluted EPS of $2.28.
- Management raised full-year 2026 guidance for total revenue, royalty revenue, adjusted EBITDA, and non-GAAP EPS.
- Strong ENHANZE royalty growth, five new collaboration agreements, and $332.8 million in second-quarter share repurchases reinforced investor confidence.
- Key risks include Merck patent litigation, partner concentration, and the longer-term execution of the Hypercon platform.
Halozyme's Business Model and Market Position
Halozyme Therapeutics, Inc. is a biopharmaceutical drug-delivery company best known for its ENHANZE platform, which uses recombinant human hyaluronidase to enable subcutaneous administration of injectable biologics. The company generates high-margin royalties from partner products that use the technology, while also selling proprietary products including Hylenex and XYOSTED. Major ENHANZE-enabled therapies include subcutaneous DARZALEX, VYVGART Hytrulo, PHESGO, OCREVUS ZUNOVO, Opdivo Qvantig, and RYBREVANT FASPRO.
Halozyme’s business model is built around recurring royalty revenue, a diversified partner base, and expanding applications for drug delivery across oncology, immunology, and neurology. Investors follow the stock closely because royalty streams convert efficiently into cash flow, and the company is positioning its newer Hypercon platform as a second long-term growth engine. To get a broader view of comparable companies, I also checked this using Tickeron’s AI Screener.
HALO Stock Price Performance Over the Last 30 Days and Quarter
Over the 30 days ended August 14, 2026, HALO rose from a closing price of $75.82 on July 15 to an available price of $98.63, a gain of about 30.1%. The sharpest move occurred after the August 6 earnings release: the stock closed at $85.76 on August 6 and jumped to $103.12 the following session, a one-day increase of roughly 20.2%, before consolidating near $98–$103 in subsequent sessions.
The quarterly trend was even stronger. From a close of $69.21 on May 14, 2026, to $98.63 on August 14, HALO advanced approximately 42.5%. The move reflects a broader re-rating that began after first-quarter results in May and accelerated when second-quarter results and raised guidance confirmed the momentum. I pulled up Tickeron’s AI Pattern Search Engine to see how similar royalty-driven setups have behaved historically.
Drivers Behind the Recent 30-Day Move
The main catalyst was Halozyme’s second-quarter 2026 report, released August 6. Total revenue rose 48% year over year to $481 million, royalty revenue increased 50% to $307.7 million, and adjusted EBITDA climbed 46% to $328.8 million. Non-GAAP diluted EPS of $2.28 compared with $1.54 a year earlier and came in well above analyst expectations.
Management also raised full-year 2026 guidance. The company now expects total revenue of $1.835 billion to $1.91 billion, royalty revenue of $1.22 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.28 billion, and non-GAAP diluted EPS of $8.65 to $9.00. Underlying royalty performance supported the outlook: DARZALEX royalties rose 27% to $152.2 million, VYVGART Hytrulo royalties rose 143% to $72.6 million, and royalties from newer launches increased about 80% sequentially.
Additional tailwinds included five collaboration and licensing agreements announced across the second quarter and July, involving partners such as GSK, Incyte, Vertex, and Oruka. These deals generated $35.5 million in upfront collaboration revenue and expanded ENHANZE and Hypercon into areas including antibody-drug conjugates and nucleic acid therapies. Share repurchases of $332.8 million during the quarter also signaled confidence in cash generation and supported per-share metrics.
Broader Drivers Over the Last Quarter
The broader quarterly advance began with first-quarter 2026 results reported May 11. Revenue rose 42% year over year to $376.7 million, royalty revenue increased 43% to $240.7 million, and non-GAAP diluted EPS reached $1.60. Halozyme reaffirmed its 2026 guidance at that time and announced a new $1 billion share repurchase authorization, with at least $400 million expected in 2026.
Through June and July, the stock benefited from sustained commercial uptake of ENHANZE-enabled products, new partnership activity, and progress on Hypercon manufacturing plans. The August earnings beat then validated the trend, showing that royalty growth was broadening beyond DARZALEX and VYVGART into newer subcutaneous launches. The combination of accelerating royalties, higher guidance, and active capital returns turned a steady uptrend into a sharper repricing.
What to Watch Next for HALO Investors
- Partner product momentum: Continued uptake of OCREVUS ZUNOVO, Opdivo Qvantig, RYBREVANT FASPRO, and TECENTRIQ HYBREZA will influence royalty growth and guidance credibility.
- Litigation risk: Halozyme’s patent infringement dispute with MRK remains a key uncertainty, with U.S. patent-review appeals expected to resolve around the end of 2026.
- Pipeline execution: Investors will monitor progress toward 13 ENHANZE development programs by year-end and preparation for first Hypercon clinical studies in 2027.
- Financial updates: Third-quarter 2026 results, updated guidance, and the pace of share repurchases will help determine whether royalty acceleration and margin trends remain intact.
AI Tools Supporting My Analysis Process
In my research workflow, I regularly review Tickeron’s AI Trading Bots to evaluate automated strategies that align with fundamental momentum like the one seen in HALO. The platform curates top-performing bots across different risk profiles and holding periods, providing useful context without replacing core analysis. Selections update based on ongoing performance, helping me consider how systematic approaches might complement the stock’s outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HALO in +3.70% Uptrend, advancing for three consecutive days on September 18, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HALO advanced for three days, in 269 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on HALO as a result. In 62 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 232 of 304 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for HALO turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 36 similar instances when the indicator turned negative. In 24 of the 36 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
HALO broke above its upper Bollinger Band on September 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (89.286) is normal, around the industry mean (25.929). P/E Ratio (32.977) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (7.968) is also within normal values, averaging (437.043).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology
Advertisement